/Investor DB

Thuja Capital — Full Portfolio

16 tracked investments · listed companies and verified rows first

Artica Therapeuticsartica-tx.cominNov 2023✓ verified

Artica Therapeutics develops orally bioavailable small molecule inhibitors that use covalent chemistry to achieve antibody-like efficacy, positioned as an "antibody-in-a-pill" approach.

BiotechDeep TechHealthtech

Tjeerd Barf(Co-founder & CEO)inArwin Ridder(Co-founder & COO)inAd IJzerman(Co-founder & SAB Chair)inJason(Chief Scientific Officer)in

Co-investorsBioGeneration VenturesSeroba Life SciencesBGV

ATROatromedical.comin✓ verified

ATRO Medical develops an artificial meniscus intended to reduce chronic knee pain and preserve the knee joint for patients and orthopedic surgeons.

BiotechHealthtechMedical DevicesNijmegen, NL

Tony van Tienen(Founder)inMaarten(CEO)

Co-investorsBOM

Cristal Therapeuticscristaltherapeutics.comin𝕏Jul 2013✓ verified

Cristal Therapeutics develops therapeutics in the life sciences sector.

BiotechDeep TechDigital HealthMedical DevicesUtrecht, NL

Dr. Cristianne Rijcken(Chief Scientific Officer and Founder)Dr. Joost Holthuis(Co-founder and former CEO)

Co-investorsBioGeneration VenturesChemelot VenturesBOMDroia VenturesBrightlands Venture Partners

Tacalyxtacalyx.com✓ verified

Tacalyx develops novel anticancer therapeutics that target Tumor-Associated Carbohydrate Antigens (TACAs), including antibody-drug conjugate programs.

BiotechDeep TechMedical DevicesBerlin, DE

Peter Seeberger(Co-founder (Prof. Dr.))Oren Moscovitz(CSO & Co-founder)

Co-investorsCreathor VenturesKurma PartnersBoehringer Ingelheim Venture FundApollo Health Ventures

Alestaalestatherapeutics.comin

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in

Co-investorsDroia VenturesFrazier Life SciencesNovartis Venture FundRV Invest GmbHFrazier Healthcare PartnersMPM BioImpact+1 more

arGEN-Xargenx.com

The company develops therapies for people with severe autoimmune diseases.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital AdvisorsBioGeneration VenturesHBM Healthcare InvestmentsMPM BioImpactOmnes CapitalPMV+3 more

Cardiac Boostercardiacbooster.comin

Cardiac Booster develops cardiac support technology for use in treating heart conditions.

BiotechHardwareHealthtechMedical DevicesGalway, IE

Florian Ludwig(CEO)inGerard Kilcommins(COO)inGreg Mann(CFO)Patrick Griffin(VP Technology Development)inJeff Grainger(VP of Legal Affairs)inDaragh Moloney(HR Director)in

Co-investorsAscension VenturesLightstone Ventures

IndiGogoindigo.in

Rahul Bhatia(Founder)Rakesh Gangwal(Founder)

Co-investorsQbic FundEra VenturesOak HC/FT

Mellon Medicalmellonmedical.comin

Mellon Medical manufactures a surgical instrument for abdominal wall closure featuring a double-pointed needle, ergonomic jaws, and atraumatic needle-suture combination.

HealthtechMedical DevicesRotterdam, NL

Co-investorsBioGeneration VenturesBOM

NutriLeadsnutrileads.cominSep 2020

NutriLeads employs in-house experts with backgrounds in food technology, microbiology, nutrition, and health across academic and industry sectors.

AgTechBiotechFoodTechHealthtechWellness & FitnessWageningen, NL

Co-investorsSHIFT Investdsm-firmenich VenturingIcos CapitalOost NL

Salvia Bioelectronicssalviabioelectronics.com

Neuromodulation therapy for migraine relief.

Eindhoven, NL

Hubert Martens(Co-founder; Chief Executive Officer)Daniel Schobben(Co-founder; Chief Innovation Officer)Dr. Wim Pollet(Co-founder; Chief Medical Officer)

Co-investorsDolby Family VenturesInkefInnovation IndustriesLevensohn Venture PartnersPanakes PartnersSHS Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

BioCerosEsoBiotecFundaMental PharmaGradient Denervation TechnologiesSmall Molecules

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.